Precise monitoring of specific biomarkers in biological fluids with accurate biodiagnostic sensors is critical for early diagnosis of diseases and subsequent treatment planning. In this work, we demonstrated an innovative biodiagnostic sensor, portable reusable accurate diagnostics with nanostar antennas (PRADA), for multiplexed biomarker detection in small volumes (~50 μl) enabled in a microfluidic platform. Here, PRADA simultaneously detected two biomarkers of myocardial infarction, cardiac troponin I (cTnI), which is well accepted for cardiac disorders, and neuropeptide Y (NPY), which controls cardiac sympathetic drive. In PRADA immunoassay, magnetic beads captured the biomarkers in human serum samples, and gold nanostars (GNSs) “antennas” labeled with peptide biorecognition elements and Raman tags detected the biomarkers via surface‐enhanced Raman spectroscopy (SERS). The peptide‐conjugated GNS‐SERS barcodes were leveraged to achieve high sensitivity, with a limit of detection (LOD) of 0.0055 ng/ml of cTnI, and a LOD of 0.12 ng/ml of NPY comparable with commercially available test kits. The innovation of PRADA was also in the regeneration and reuse of the same sensor chip for ~14 cycles. We validated PRADA by testing cTnI in 11 de‐identified cardiac patient samples of various demographics within a 95% confidence interval and high precision profile. We envision low‐cost PRADA will have tremendous translational impact and be amenable to resource‐limited settings for accurate treatment planning in patients.

中文翻译：

---

PRADA：便携式可重复使用的精确诊断与纳米星天线用于多重生物标志物筛选


使用准确的生物诊断传感器精确监测生物体液中的特定生物标志物对于疾病的早期诊断和后续治疗计划至关重要。在这项工作中，我们展示了一种创新的生物诊断传感器，便携式可重复使用的纳米星天线精确诊断（PRADA），用于在微流体平台中实现小体积（~50μl）的多重生物标志物检测。在这里，PRADA 同时检测了心肌梗塞的两种生物标志物：心肌肌钙蛋白 I (cTnI)（广泛接受用于治疗心脏疾病）和神经肽 Y (NPY)（控制心脏交感神经驱动）。在 PRADA 免疫测定中，磁珠捕获人血清样本中的生物标志物，而标记有肽生物识别元件和拉曼标签的金纳米星（GNS）“天线”通过表面增强拉曼光谱（SERS）检测生物标志物。利用肽缀合的 GNS-SERS 条形码实现高灵敏度，cTnI 的检测限 (LOD) 为 0.0055 ng/ml，NPY 的 LOD 为 0.12 ng/ml，与市售检测试剂盒相当。 PRADA 的创新还在于同一传感器芯片的再生和重复使用约 14 个周期。我们通过在 95% 置信区间和高精度概况内测试 11 名不同人口统计数据的未识别心脏病患者样本中的 cTnI 来验证 PRADA。我们预计低成本的 PRADA 将产生巨大的转化影响，并适合资源有限的环境，为患者制定准确的治疗计划。